The company has a robust balance sheet enabling continued development of its NMDA and GABAA platform, positioned for long-term growth as total sales are projected to reach approximately $400 million by 2028. The lead commercial product, Zurzuvae, partnered with Biogen, is expected to gain significant traction in the treatment of postpartum depression due to its rapid onset of action and concise treatment regimen.
Cyborg Score Rationale
Sage reported a 264% increase in Q2 2025 revenue, indicating significant growth in its financial performance. However, the company maintains an operating margin of -171.2% and return on equity of -60.4%, reflecting ongoing losses despite commercialization progress.
Top Insights
(July 2025) Q2 2025 revenue surged 264% with strong prescription growth of 33% following sales force expansion
(March 2026) Analyst consensus rating is Hold with price target around $8.40-$9.37
Leading product Zurzuvae for postpartum depression in partnership with Biogen targeting significant unmet medical need
Pipeline includes SAGE-324 for seizures in developmental epileptic encephalopathies and multiple earlier-stage programs (SAGE-319, SAGE-039, SAGE-817)